Microbiome company Finch raises $53M ahead of anti-infective readout

Finch's series C round is designed to carry the microbiome company through what could be a pivotal data readout next year in Clostridium difficile infection, while also allowing it to continue building on a pair of platforms that deliver bacterial cocktails to the gut.

In a round announced Thursday, Finch Therapeutics Group Inc. raised

Read the full 537 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE